AlphAIAlphAI — Financial news for AI agents
investing.comOCT 302 min read$NRXP

NRx Pharmaceuticals receives FDA approval for ketamine drug

NRx Pharmaceuticals (NASDAQ:NRXP) received FDA approval for its Preservative-Free Ketamine drug ahead of the November 10 goal date. The drug, manufactured without benzethonium chloride, addresses a shortage of ketamine injections. The company will host a conference call to discuss the approval.

Original reporting
investing.com
Published Oct 30, 2026, 11:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 11:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$NRXP
Bullish
high confidence
Mentioned
$NRXP
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NRXPBullishHigh
01

Why it matters

The approval could unlock a new revenue stream and improve the company's pipeline credibility.

02

Market read

First‑time FDA clearance for a ketamine product likely triggers a positive price reaction for NRXP.

03

What to watch

Potential reimbursement challenges and competition from existing ketamine products could temper upside.

Relevance 9/10Novelty 9/10Timing: today

Background

NRx Pharmaceuticals is a clinical‑stage biopharma focused on CNS disorders; ketamine is on a shortage list, making this approval strategically important.

Company-level read

Ticker impact

$NRXPBullishHigh confidence
Context

NRx Pharmaceuticals received FDA approval for its preservative‑free ketamine injection, a first‑time regulatory clearance disclosed in this article.

Expected impact

upward pressure as investors price in new product launch and market share gains

Evidence & confidence

The FDA approval is a primary, material event for a clinical‑stage biotech; market typically reacts positively to new drug clearances.

Market effects

Sector

May lift other ketamine or CNS‑drug developers as the shortage narrows and sets a precedent for preservative‑free formulations.

Regional

US biotech sector could see modest gains; hospital drug procurement markets may adjust sourcing strategies.

Global

Limited to US and global markets where ketamine is used medically; no broad macro effect.

Counterpoint

What could challenge this read

If the market has already priced in the approval, the stock could see a short‑term sell‑off on profit taking.

Key entities

  • Executive
    Jonathan Javitt

    Chairman and CEO of NRx Pharmaceuticals, quoted on the approval.

  • Contract Manufacturer
    Nephron Pharmaceuticals

    Facility producing the preservative‑free ketamine for NRx.

Read at source← All news

StoryFDA approves NRx’s preservative‑free ketamine injection ahead of target date

Also covered by

5 outlets

Related articles

OCT 30
$NRXPMedAI 8/10

NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection

NRx Pharmaceuticals (NASDAQ:NRXP) received FDA approval for its preservative-free ketamine injection, addressing a national drug shortage. The company's manufacturing technology allows for faster production. NRx plans to target hospitals, wholesalers, and clinics, with initial focus on converting top-tier hospital customers. The company expects to introduce additional ketamine products in 2027 and is developing other CNS treatments, including NRX-101 for bipolar depression.

finance.yahoo.com7 min
OCT 30
$NRXPHighAI 9/10

Why is NRX Pharmaceuticals stock surging today?

NRX Pharmaceuticals' stock rose 14.3% in pre-market trading after FDA approval of its Preservative-Free Ketamine, ahead of the expected November 10 date. The company completed pre-launch manufacturing requirements and received an $11.25 million DARPA contract for a Phase 3 trial of NRX-101. CEO Jonathan Javitt expressed excitement about the market launch.

investing.com2 min
OCT 30
$NRXPHighAI 8/10

NRx Pharmaceuticals Secures FDA Nod For Preservative-Free Ketamine Ahead Of Target Date; Stock Up

NRx Pharmaceuticals (NRXP) received FDA approval for its preservative-free ketamine injection, ahead of the November 10 target date. The company claims the formulation addresses concerns about potential toxicity from the preservative BZT. NRx has supply ready for U.S. distribution and is manufacturing the product with Nephron Pharmaceuticals. The stock was up 16.60% in pre-market trading.

rttnews.com1 min
OCT 30
$NRXPHighAI 9/10

NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date

NRx Pharmaceuticals (NRXP) received FDA approval for its preservative-free ketamine injection ahead of the November 10 goal date. The company aims to address drug shortages and reshoring manufacturing. NRXP will host a conference call on October 30, 2026, to discuss the approval. The company has other drug candidates in development, including NRX-100 and NRX-101, with designations for treating depression and suicidality.

finance.yahoo.com3 min
OCT 30
$NRXPHighAI 9/10

The FDA approved ketamine without a preservative found in every currently available ketamine injection.

NRx Pharmaceuticals (NRXP) announced FDA approval for its preservative-free ketamine injection, ahead of the November 10 goal date. The product lacks benzethonium chloride, a toxic preservative in current ketamine injections. NRx aims to address the ketamine shortage and reshored manufacturing to the U.S. with Nephron Pharmaceuticals. The company will host a conference call on October 30 to discuss the approval.

stocktitan.net2 min